DexCom Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Explore the Complete Growth Strategy Behind the Preview
This DexCom Balanced Scorecard Analysis gives you a clear, company-specific view of DexCom's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual report content, so you can see exactly what you're getting before buying. Purchase the full version for the complete ready-to-use analysis.
Benefits
Outcome Proof
DexCom's CGM delivers a glucose reading every 5 minutes, 288 checks a day, so a Balanced Scorecard can link usage to time in range, A1C trends, and far fewer fingersticks. That makes the value case easier to prove with clinicians and payers, not just investors.
In major CGM studies, time in range has risen by about 10 percentage points, while A1C typically falls by about 0.5 to 1.0 points. Those are clear outcome markers, so DexCom can show health gains alongside 2025 revenue and margin delivery.
Daily Engagement
DexCom's CGM sends glucose readings every 5 minutes, so a user can see up to 288 data points a day, plus alerts for highs and lows. That makes daily touchpoints easy to track in a Balanced Scorecard through active-user retention, app opens, and alert-response rates. In 2025, the model's value is clear: more frequent use means more chances for DexCom to become part of daily diabetes care.
Refill Visibility
DexCom's consumable model gives the scorecard a steady demand rhythm because every sensor wears out and must be replaced. Refill cadence, prescription starts, and churn show whether the installed base is growing and staying loyal. With 2024 revenue at $4.03 billion, refill visibility stays central to tracking repeat demand and revenue durability.
Quality Discipline
Quality discipline matters at DexCom because CGM value depends on sensor accuracy, uptime, and alert reliability. A balanced scorecard can link internal targets to fewer defect escapes, fewer service calls, and fewer patient complaints, which cuts rework and protects trust. In 2025, that kind of control is central for a device business where even small quality slips can hit usage, support costs, and repeat sales.
Provider Trust
DexCom's trend reports and alerts help providers make tighter therapy calls, which can lift trust and lead to more referrals. In a balanced scorecard, track clinic adoption, data-sharing use, and prescription conversion to see if DexCom is gaining share in the care pathway. When providers see fewer blind spots in glucose data, they are more likely to keep DexCom in the plan.
DexCom's Daily Data Drives Better Outcomes and Repeat Sales
DexCom's benefits show up in daily use, better outcomes, and repeat sales: CGM data every 5 minutes means 288 readings a day, while major studies show A1C down 0.5 to 1.0 points and time in range up about 10 points. In FY2025, that supports retention, payer value, and margin discipline.
| Benefit | Metric |
|---|---|
| Daily engagement | 288 readings/day |
| Clinical gain | A1C -0.5 to -1.0 |
| Time in range | +10 pts |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Attribution Noise
Attribution noise is a real drawback for DexCom: the device can show glucose in real time, but A1C and time-in-range still depend on diet, insulin dosing, and clinician follow-up. That makes it hard to credit every outcome gain to DexCom alone. In CGM studies, time-in-range often rises by about 8 to 10 percentage points, but the size of that lift varies with patient behavior, so the signal is noisy.
Signal Gaps
Signal gaps matter because DexCom's CGM data is built on 5-minute readings over a 10-day wear period, so any dropout can skew the Balanced Scorecard and hide real patient trends. Adhesion failures, Bluetooth loss, or sensor drift can trigger missed alerts, which weakens user trust and raises churn risk. With each missed reading, the system's clinical value falls, and alert fatigue can make customers ignore the next warning.
Reimbursement Risk
Reimbursement risk stays a key drag for DexCom. Even with strong 2025 product demand, prescription growth can slow fast if payer coverage tightens, prior authorization gets stricter, or out-of-pocket cost rises. U.S. Medicare Part B still covers continuous glucose monitors for millions of eligible patients, so any payer pullback can hit adoption and sales mix quickly.
KPI Overload
DexCom's balanced scorecard can get too broad because a CGM maker must watch product quality, FDA compliance, and payor uptake at the same time. If leadership tracks dozens of KPIs, the core ones can get buried: defect rate, active users, and gross margin. That matters when one weak metric can hit the 2025 operating plan fast, since margin swings and recall risk move earnings quickly.
Compliance Burden
DexCom's compliance burden is a real drag on process scores: every audit, validation run, and quality-system check can slow work even when demand is strong. In 2025, that means more time and spend tied to FDA-grade controls instead of faster launches, so operating leverage can slip. For a device maker, the downside is simple: more regulation means higher cost, slower cycle time, and less room for error.
DexCom's Key Risk: Noise, Gaps, and Reimbursement Pressure
DexCom's biggest drawback is attribution noise: CGM can improve time-in-range by about 8-10 percentage points, but diet, insulin dosing, and follow-up also drive the result. Missed 5-minute readings, sensor drift, or Bluetooth loss can weaken trust and blur the balanced scorecard. Reimbursement risk is still real if payer coverage tightens.
| Drawback | Key figure |
|---|---|
| Wear window | 10 days |
| Reading interval | 5 minutes |
| Time-in-range lift | 8-10 pp |
What You See Is What You Get
DexCom Reference Sources
This is the actual DexCom Balanced Scorecard analysis document you'll receive after purchase – no sample, no placeholder. The preview shown here is pulled directly from the full report, so what you see is what you get. Once your order is complete, the full document is unlocked for immediate download.
Frequently Asked Questions
It measures whether DexCom's CGM is turning product use into better diabetes control and reliable execution. The most useful indicators are time in range, A1C trend, sensor uptime, alert accuracy, and on-time shipment. If those move together, management can connect clinical value with operational quality and cash generation.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.